PMID- 12203106
OWN - NLM
STAT- MEDLINE
DCOM- 20021017
LR  - 20151119
IS  - 0344-5704 (Print)
IS  - 0344-5704 (Linking)
VI  - 50
IP  - 3
DP  - 2002 Sep
TI  - Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion 
      protein Enbrel in patients with refractory hematologic malignancies.
PG  - 237-42
AB  - PURPOSE: Tumor necrosis factor-alpha (TNF-alpha) is an important effector and 
      regulatory cytokine involved in the pathophysiology of hematologic malignancies, 
      including hairy cell leukemia (HCL), chronic lymphocytic leukemia (CLL), 
      agnogenic myeloid metaplasia (AMM) and Philadelphia-negative myeloproliferative 
      disorders (MPD). We conducted a pilot study to assess the safety of the soluble 
      TNF receptor, etanercept (p75 TNFR:Fc; Enbrel) in patients with refractory 
      hematologic malignancies. METHODS: Patients were eligible if they had refractory 
      HCL, CLL, AMM, or Philadelphia-negative MPD. Enbrel was administered twice weekly 
      at a dose of 25 mg subcutaneously for a minimum of eight doses, and was continued 
      in patients without overt progression. RESULTS: Among the 26 patients enrolled on 
      study, 25 patients were evaluable. Nine patients had AMM, eight CLL, three HCL, 
      and five Philadelphia-negative MPD. Their median age was 60 years (range 30-83 
      years). A total of 70 courses consisting of 486 doses of Enbrel were 
      administered. Enbrel was well tolerated, without any overt increase in infectious 
      episodes. Stable disease/no objective response was seen in 22 patients (88%) and 
      progression in 3 patients (12%). Three patients with AMM improved (two showed 
      hematologic improvement, and one showed a reduction in liver and spleen size), 
      and two patients (one with CLL and one with Philadelphia-negative MPD) showed 
      improvement in disease-related symptoms. CONCLUSIONS: Enbrel was well tolerated, 
      but no responses were noted in these immunosuppressed patients with refractory 
      hematologic malignancies.
FAU - Tsimberidou, Apostolia-Maria
AU  - Tsimberidou AM
AD  - Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, 
      Texas, 77030, USA.
FAU - Thomas, Deborah
AU  - Thomas D
FAU - O'Brien, Susan
AU  - O'Brien S
FAU - Andreeff, Michael
AU  - Andreeff M
FAU - Kurzrock, Razelle
AU  - Kurzrock R
FAU - Keating, Michael
AU  - Keating M
FAU - Albitar, Maher
AU  - Albitar M
FAU - Kantarjian, Hagop
AU  - Kantarjian H
FAU - Giles, Francis
AU  - Giles F
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20020726
PL  - Germany
TA  - Cancer Chemother Pharmacol
JT  - Cancer chemotherapy and pharmacology
JID - 7806519
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunologic Factors)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Etanercept
MH  - Female
MH  - Hematologic Neoplasms/*drug therapy
MH  - Humans
MH  - Immunocompromised Host
MH  - Immunoglobulin G/administration & dosage/*pharmacology
MH  - Immunologic Factors/administration & dosage/pharmacokinetics/*pharmacology
MH  - Injections, Subcutaneous
MH  - Male
MH  - Middle Aged
MH  - Receptors, Tumor Necrosis Factor/administration & dosage
MH  - Treatment Outcome
EDAT- 2002/08/31 10:00
MHDA- 2002/10/18 04:00
CRDT- 2002/08/31 10:00
PHST- 2002/02/12 00:00 [received]
PHST- 2002/05/02 00:00 [accepted]
PHST- 2002/08/31 10:00 [pubmed]
PHST- 2002/10/18 04:00 [medline]
PHST- 2002/08/31 10:00 [entrez]
AID - 10.1007/s00280-002-0479-6 [doi]
PST - ppublish
SO  - Cancer Chemother Pharmacol. 2002 Sep;50(3):237-42. doi: 
      10.1007/s00280-002-0479-6. Epub 2002 Jul 26.